Home/Investors/Polaris Partners Polaris Partners
Biotech Investor · 15 portfolio companies
Portfolio Companies
| Company | Stage | Valuation | Focus |
|---|
| Scholar Rock | Phase 3 | $5.9B | Neuromuscular, Cardiometabolic |
| Scholar Rock Holding | Phase 3 | $5.7B | Neuromuscular, Cardiometabolic Disorders |
| Tectonic Therapeutic | Phase 1 | $584.0M | Cardiopulmonary, Fibrotic Diseases |
| CAMP4 Therapeutics | Phase 1/2 | $217.0M | Central Nervous System (CNS), Metabolic Diseases |
| Alector | Phase 3 | $200.4M | Neurodegenerative Diseases, Neurology |
| Volastra Therapeutics | preclinical | — | Oncology, Genetics & Genomics |
| Pretzel Therapeutics | preclinical | — | Rare Disease, Metabolic Disorders |
| Kallyope | Phase 2 | — | Migraine, Metabolic Disorders |
| Lyndra | Phase 3 | — | Schizophrenia, HIV Prevention |
| Drawbridge Health | Approved | — | Diabetes, Chronic Disease Management |
| Engine Biosciences | Pre-clinical | — | Oncology |
| Nido Biosciences | preclinical | — | Neuroscience, Immunology |
| Seismic Therapeutic | preclinical | — | Immunology, Autoimmune Diseases |
| NanoMed Systems | platform | — | Drug Delivery, Oncology |
| GeneEdit Therapeutics | preclinical | — | Genetics & Genomics, Rare Diseases |